IPIX (Innovation Pharmaceuticals) Total Liabilities: $5.51 Mil (As of Sep. 2023)


What is Innovation Pharmaceuticals Total Liabilities?

Innovation Pharmaceuticals IPIX Total Liabilities is $5.51 Mil as of Sep. 2023.

Innovation Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2023 was $5.51 Mil.

Innovation Pharmaceuticals's quarterly Total Liabilities increased from Mar. 2023 ($5.28 Mil) to Jun. 2023 ($5.48 Mil) and increased from Jun. 2023 ($5.48 Mil) to Sep. 2023 ($5.51 Mil).

Innovation Pharmaceuticals's annual Total Liabilities declined from Jun. 2021 ($6.79 Mil) to Jun. 2022 ($5.65 Mil) and declined from Jun. 2022 ($5.65 Mil) to Jun. 2023 ($5.48 Mil).

Innovation Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Innovation Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovation Pharmaceuticals Total Liabilities Chart

Innovation Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.18 7.79 6.79 5.65 5.48

Innovation Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.92 5.61 5.28 5.48 5.51

Innovation Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Innovation Pharmaceuticals's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.021+(0+0.457
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=5.48

Total Liabilities=Total Assets (A: Jun. 2023 )-Total Equity (A: Jun. 2023 )
=7.517-2.039
=5.48

Innovation Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.048+(0+0.457
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=5.51

Total Liabilities=Total Assets (Q: Sep. 2023 )-Total Equity (Q: Sep. 2023 )
=6.667-1.162
=5.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $5.51 Mil mean?
Innovation Pharmaceuticals (IPIX) has a Total Liabilities of $5.51 Mil as of Sep. 2023. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Innovation Pharmaceuticals and its competitors.
Is Innovation Pharmaceuticals' Total Liabilities too high?
Innovation Pharmaceuticals' current Total Liabilities is $5.51 Mil.
How does Innovation Pharmaceuticals' Total Liabilities compare to AXIM and RNAZ?
Innovation Pharmaceuticals' Total Liabilities of $5.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Innovation Pharmaceuticals and its competitors. Innovation Pharmaceuticals's current Total Liabilities is $5.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovation Pharmaceuticals stock overvalued right now?
Innovation Pharmaceuticals (IPIX) has a current Total Liabilities of $5.51 Mil. The current Total Liabilities is $5.51 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Innovation Pharmaceuticals (IPIX), the current Total Liabilities is $5.51 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innovation Pharmaceuticals Business Description

Address 301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.